1150P - Phase II clinical trial of peptide vaccination for advanced head and neck cancer patients induced immune responses and prolonged OS.
| Date | 10 September 2017 |
| Event | ESMO 2017 Congress |
| Session | Poster display session |
| Topics | Cancer in Adolescents Cancer Immunology and Immunotherapy Head and Neck Cancers |
| Presenter | YOSHIHIRO YOSHITAKE |
| Citation | Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376 |
| Authors |
Y. YOSHITAKE1, D. Fukuma2, M. Hirayama2, H. Nakayama2, H. Ogi2, M. Shinohara2
|
Abstract
Background
The peptides derived from ideal cancer-testis antigens, including LY6K, CDCA1 and IMP3 (identified using genome-wide cDNA microarray analyses), were utilized in immunotherapy for head and neck squamous cell cancer (HNSCC). In this trial, we analyzed the immune response to and safety and efficacy of vaccine therapy.
Methods
A total of 40 patients with advanced HNSCC were enrolled in this trial of peptide vaccine therapy, and the OS, PFS and immunological response were evaluated using enzyme-linked ImmunoSpot (ELISPOT) and pentamer assays. The peptides were subcutaneously administered weekly with IFA. The primary endpoints were evaluated based on differences between HLA-A*2402-positive (A24(+)) patients treated with peptide vaccine therapy and –negative (A24(-)) patients treated without peptide vaccine therapy among those with advanced HNSCC.
Results
Our cancer vaccine therapy was well tolerated. The OS of the A24(+)v accinated group (n = 40) was statistically significantly longer than that of the A24(-) group (n = 18) (MST 4.9 vs. 3.5 month, respectively, p
Conclusions
The immune response induced by this peptides vaccine may improve the prognosis of patients with advanced HNSCC.
Clinical trial identification
Legal entity responsible for the study
Yoshihiro Yoshitake
Funding
None
Disclosure
All authors have declared no conflicts of interest.